In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sun Pharmaceutical Industries Ltd.

https://www.sunpharma.com/

Latest From Sun Pharmaceutical Industries Ltd.

Sun Pharma’s Ranbaxy Fails In Bid To Dodge Antitrust Suit

A US lawsuit accusing Sun Pharma’s Ranbaxy of violating racketeering and antitrust laws, thereby maintaining artificially inflated prices for three blockbuster drugs, is now set to go to trial in January next year, after a US district court in Massachusetts denied all motions for summary judgment.

Legal Issues Generic Drugs

Consolidation And COVID See Off-Patent Industry Rankings Rewritten

After an extraordinary year that saw demand patterns and the supply chain upended by the COVID-19 pandemic, as well as a major merger that has transformed one of the global off-patent industry’s biggest players, Generics Bulletin’s Top 50 has once again seen significant changes.

Sales & Earnings Biosimilars

India’s 'Thousand Talents' Moment And Models To Shift Gears In R&D

Industry leaders including Sanofi's ex-CEO and the chiefs of Sun, Lupin, Glenmark, Dr Reddy’s and Cipla discuss how India could leapfrog its pharma R&D efforts. Could the South Korea model or a hybrid approach including bringing back top talent bolster the country’s efforts to emerge as a global innovation hot spot?

India Research & Development

Clozapine REMS Program Paused After Problems With Re-Certification

US FDA says pharmacists may dispense the antipsychotic without a REMS authorization and wholesalers may continue to ship it during temporary suspension of REMS. A high call volume and long wait times have impacted patient access since the modified REMS launched on 15 November.

Risk Management Drug Review
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Aditya Acquisition Company ltd
    • Caraco Pharmaceutical Laboratories, Ltd.
    • DUSA Pharmaceuticals, Inc.
    • InSite Vision, Inc.
    • JSC Biosintez
    • Ocular Technologies
    • Pola Pharma Inc.
    • Ranbaxy Laboratories Limited
    • Ranbaxy Solus
    • Solus Care
    • Sun Ophthalmics
    • Sun Pharma Global FZE
UsernamePublicRestriction

Register